Haematology and Coagulation Disorders
Octapharma AG focuses on clinical research in haematology with a strong emphasis on disorders affecting blood clotting and anticoagulant management. Its studies address conditions linked to impaired coagulation control in surgical, emergency, and perioperative settings.
- Antithrombin deficiency
- Heparin resistance
- Thrombotic and thromboembolic events
The sponsor’s research activity includes both acquired and congenital antithrombin deficiency, reflecting interest in restoring anticoagulant balance during surgery and parturition.
Perioperative Haemostatic Management
A major area of interest is the control of perioperative bleeding and the maintenance of haemostatic efficacy in patients undergoing complex procedures. Research includes treatment support for individuals with inherited bleeding disorders and those requiring urgent surgical care.
- Major surgery
- Cardiac surgery
- Emergency haemostasis
Clinical work in this area spans patients with haemophilia A, including women and girls, as well as individuals managed with factor VIII-based support in operative settings.
Reversal of Anticoagulant Effect
Octapharma AG also pursues research in the management of acute major bleeding associated with direct oral anticoagulants, particularly therapies targeting factor Xa inhibition. This reflects a focus on urgent reversal strategies in high-risk bleeding situations.
- DOAC-associated bleeding
- Factor Xa inhibitor reversal
- Prothrombin complex concentrate
These studies are centred on restoring effective haemostasis in patients requiring immediate control of bleeding complications.
Haemophilia A and Specialised Patient Populations
The sponsor maintains a clear therapeutic interest in haemophilia A, including perioperative care in patients receiving emicizumab prophylaxis and in female patients with inherited bleeding disorders. The research landscape extends to populations with distinct clinical needs and surgical challenges.
- Severe haemophilia A
- Women and girls with haemophilia A
- Perioperative factor VIII support
These trials highlight attention to individualised haemostatic care across diverse patient groups requiring specialised bleeding management.
